Immune Thrombocytopenia

Ianalumab Plus Eltrombopag Extends Disease Control in Phase 3 ITP Study Published in NEJM

Peer‑reviewed results point to a finite, disease‑modifying strategy for previously treated patients, with regulatory decisions still ahead.